Our Pricing

Wegovy 1.7mg Price UK: £79.00 Next Day Delivery

Searching for transparent wegovy 1.7mg price uk information? At Cured Pharmacy, Wegovy 1.7mg is available from £79.00 with next day delivery, free online consultation with UK prescribers, and 100% discreet packaging. Our upfront pricing means you'll know the exact cost before your clinical assessment begins.

Understanding Wegovy 1.7mg in Your Weight Loss Journey

Wegovy 1.7mg represents the third escalation dose in the semaglutide titration schedule licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. This once-weekly injectable medication mimics GLP-1, a naturally occurring hormone that regulates appetite and food intake at the hypothalamic level.

In the landmark STEP 1 clinical trial, participants using semaglutide 2.4mg (the maintenance dose after titration through 1.7mg) achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. The 1.7mg dose serves as a crucial bridge, allowing your body to adapt gradually whilst minimising gastrointestinal side effects commonly reported during rapid dose escalation.

At Cured Pharmacy, our UK-registered clinical team assesses your suitability for Wegovy based on your medical history, current medications, and weight management goals. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees every prescription to ensure clinical appropriateness and patient safety throughout your treatment journey.

Wegovy 1.7mg Price UK: What You're Actually Paying For

Transparent pricing remains frustratingly rare in UK online pharmacy, with many providers hiding costs until after lengthy consultations. At Cured Pharmacy, Wegovy 1.7mg costs £79.00 — a price you'll see before starting your free three-minute clinical assessment. This upfront approach reflects our commitment to honest healthcare without hidden consultation fees or surprise charges at checkout.

your £10 investment includes the genuine UK-licensed Wegovy 1.7mg pen, clinical assessment by a GMC-registered prescriber, pharmacy dispensing and safety checks by our GPhC-registered team, and next day delivery in discreet, unmarked packaging. We guarantee the lowest prices in the UK — if you find Wegovy 1.7mg cheaper elsewhere from a legitimate UK-registered pharmacy, we'll match it.

Many patients ask why prices vary so dramatically across UK pharmacies. The answer lies in operational efficiency, bulk purchasing agreements with manufacturers, and business model choices. At Cured Pharmacy, we've optimised every step to pass savings directly to you whilst maintaining the highest clinical and regulatory standards required by the General Pharmaceutical Council.

Comparing Wegovy 1.7mg Price UK Market Rates

The UK market for GLP-1 receptor agonists has expanded rapidly since Wegovy's MHRA approval, with pricing structures varying considerably between providers. Whilst we cannot name specific competitors, typical market rates often exceed our £79.00 price point by £79.00 or more per pen. Our lowest price guarantee ensures you're receiving competitive UK pricing without compromising on pharmaceutical quality or clinical oversight.

Remember that any legitimate UK pharmacy must include prescriber assessment costs in their pricing model — there's no such thing as a 'prescription-free' Wegovy service in the UK. At Cured Pharmacy, consultation fees are built into our transparent £79.00 price, so you'll never encounter unexpected charges during checkout.

How Wegovy 1.7mg Works: Clinical Mechanism Explained

Semaglutide, the active pharmaceutical ingredient in Wegovy, functions as a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to native human GLP-1 [3]. When you inject Wegovy 1.7mg subcutaneously once weekly, semaglutide binds to GLP-1 receptors in multiple tissues including the pancreas, brain, and gastrointestinal tract, triggering a cascade of metabolic effects that support weight loss.

The primary mechanisms include delayed gastric emptying (you feel fuller for longer after meals), reduced appetite signalling in the hypothalamus, and improved glucose-dependent insulin secretion. Unlike older weight loss medications that simply suppress appetite through central nervous system stimulation, Wegovy works with your body's natural satiety pathways to create sustainable behavioural changes around food intake [1][2].

Clinical data demonstrates that the 1.7mg dose produces measurable weight loss whilst serving as a tolerance-building step toward the 2.4mg maintenance dose. Patients typically spend four weeks at 1.7mg before escalating, allowing gastrointestinal adaptation and minimising the risk of treatment discontinuation due to side effects.

Expected Results at the 1.7mg Dose

During your four weeks at Wegovy 1.7mg, you may notice progressive appetite reduction and increased meal-time satiety compared to lower titration doses. Whilst the full 14.9% average weight loss seen in STEP 1 trials occurred at the 2.4mg maintenance dose [2], many patients report meaningful weight reduction beginning at 1.7mg, particularly when combined with lifestyle modifications including a reduced-calorie diet and increased physical activity.

Individual responses vary considerably based on baseline metabolic health, adherence to lifestyle interventions, and genetic factors affecting GLP-1 receptor sensitivity. Your UK prescriber will monitor your progress and determine the optimal timing for dose escalation based on your tolerance and clinical response.

Wegovy 1.7mg Dosing Schedule and Administration

Wegovy follows a structured five-step titration protocol designed by Novo Nordisk and approved by the MHRA: 0.25mg for four weeks, 0.5mg for four weeks, 1.0mg for four weeks, 1.7mg for four weeks, then 2.4mg as the maintenance dose [1]. This gradual escalation significantly reduces the incidence of gastrointestinal adverse events — the most common reason for treatment discontinuation in clinical trials.

Each Wegovy 1.7mg pen contains a single pre-filled dose administered subcutaneously once weekly, ideally on the same day each week. Injection sites include the abdomen, thigh, or upper arm, rotated weekly to prevent lipodystrophy. The pen design requires no manual dose adjustment — simply attach a new needle, dial the dose (which is preset to 1.7mg), and inject. Most patients complete administration in under 30 seconds.

If you miss a dose and fewer than five days have passed, inject as soon as you remember. If more than five days have elapsed, skip the missed dose and resume your regular schedule. Never double-dose to compensate. Our clinical team provides detailed administration guidance during your consultation, and you'll receive manufacturer instructions with every pen delivery.

Common Side Effects and Clinical Management at 1.7mg

Gastrointestinal symptoms represent the most frequently reported adverse events with Wegovy 1.7mg, affecting approximately 44% of participants in STEP clinical trials [2]. These include nausea (most common), diarrhoea, constipation, vomiting, and abdominal discomfort. Symptoms typically emerge within the first few weeks of each dose escalation and often resolve spontaneously as your body adapts to higher semaglutide levels.

Clinical strategies to minimise side effects include eating smaller, more frequent meals rather than three large meals daily; avoiding high-fat and heavily spiced foods during the first two weeks at 1.7mg; staying well-hydrated throughout the day; and eating slowly to allow satiety signals to register before overconsumption. Many patients find that symptoms decrease significantly by week three of the 1.7mg dose.

Serious adverse events remain rare but require immediate medical attention: persistent severe abdominal pain (possible pancreatitis), visual changes, symptoms of thyroid tumours (neck lump, hoarseness, difficulty swallowing), or signs of gallbladder disease. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains uncertain [3]. Your prescriber will assess your personal and family history for thyroid cancer and multiple endocrine neoplasia syndrome type 2 before prescribing.

When to Contact Your Prescriber

Contact our clinical team immediately if you experience persistent vomiting preventing fluid intake for more than 24 hours, severe abdominal pain radiating to the back, yellowing of skin or eyes, or sudden vision changes. These symptoms may indicate serious complications requiring urgent assessment. Our UK-registered prescribers remain available throughout your treatment journey to address concerns and optimise your clinical outcomes.

For routine side effect management or questions about dose escalation timing, you can reach Cured Pharmacy at (+44) 116 4646009 during business hours or submit a query through your patient portal for response within 24 hours.

Starting Your Wegovy 1.7mg Treatment with Cured Pharmacy

Beginning your Wegovy journey at Cured Pharmacy takes under three minutes with our streamlined online consultation. You'll answer questions about your medical history, current medications, weight management goals, and any contraindications to GLP-1 therapy. Our UK-registered prescribers review every assessment individually — this isn't an automated algorithm, but genuine clinical oversight by GMC-registered doctors who specialise in weight management.

If Wegovy proves clinically appropriate based on MHRA licensing criteria and your individual health profile, your prescription is issued electronically to our GPhC-registered pharmacy team. We dispense genuine UK-licensed Wegovy pens sourced directly from licensed wholesalers, never grey-market imports or counterfeit products. Every pen includes manufacturer authentication features you can verify.

Next day delivery comes as standard with discreet, unmarked packaging that reveals nothing about contents to neighbours or household members. We dispatch via tracked courier Monday through Friday, with orders placed before 3pm typically arriving the following business day. Your Wegovy 1.7mg pen arrives in temperature-controlled packaging to maintain the 2°C to 8°C storage requirement during transit, with cold packs and insulation meeting pharmaceutical transport standards.

Ongoing treatment couldn't be simpler: log into your patient portal four weeks before your next dose is due, confirm you're ready to continue (or escalate to 2.4mg if appropriate), and your prescription renews automatically subject to prescriber approval. We'll send reminder emails so you never risk treatment interruption. Our lowest price guarantee applies to every refill, and you can cancel anytime without penalty or pressure.

Why Choose Cured Pharmacy for Wegovy 1.7mg

As a fully registered UK pharmacy (GPhC 9012511) with superintendent pharmacist oversight from Tarun Kumar (GPhC 2233073), we combine regulatory compliance with patient-focused service. Our transparent pricing model means the £79.00 you see is the £79.00 you pay — no hidden consultation fees, no surprise delivery charges, no membership subscriptions required.

We've helped thousands of UK patients access weight management treatments through our online service, maintaining a 4.8-star Trustpilot rating based on genuine customer reviews. Every prescription undergoes dual clinical review by both the prescriber and our pharmacy team, ensuring safety checks catch potential drug interactions or contraindications before dispensing. Your health outcomes matter more than sales targets, which is why our prescribers decline approximately 12% of applications where Wegovy isn't clinically appropriate.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Public Assessment Report: Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen (semaglutide). MHRA. https://products.mhra.gov.uk/
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Novo Nordisk. (2023). Wegovy (semaglutide) injection 2.4 mg: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities, as an adjunct to a reduced-calorie diet and increased physical activity. Individual results may vary. Superintendent pharmacist: Tarun Kumar (GPhC 2233073). GPhC Registration: 9012511.